Show simple item record

dc.contributor.authorVan Witzenburg, Melissa
dc.date.accessioned2009-07-08T22:54:24Z
dc.date.available2009-07-08T22:54:24Z
dc.date.issued2009-07-08T22:54:24Z
dc.date.submittedMay 2009
dc.identifier.urihttp://hdl.handle.net/1928/9320
dc.description.abstractThere are more than 15, 000 approved prescription and over-the-counter drugs, diagnostics, and intravenous supplementation products in the United States. Due to the increased number of patients using medications it is important that dental providers are aware of common adverse oral complications. The most commonly seen adverse oral effects of medications are xerostomia, gingival hypertrophy, angular cheilitis, and mucositis. The purpose of this study was to examine dental providers, “subjects” knowledge of adverse oral effects of low-dose methotrexate, diltiazem, cyclosporine, isotretinoin, and lisinopril. Four of the five hypotheses tested demonstrated high P-values, therefore; they were consistent with the null hypothesis. However, these four hypotheses yielded insight into areas of further study. When evaluating the number of continuing education hours that subjects participate in annually compared to their responses on the survey, a statistically significant difference was demonstrated. A P-value of 0.022 was obtained, with subjects participating in 26+ hours of continuing education scoring an average of 0.629 higher than those who participate in 25 or fewer hours of continuing education annually. Data suggests that further studies are needed to evaluate where students are instructed on adverse oral effects in an educational setting and how much time is spent on the subject matter. Other areas of further investigation would include a study of established dental providers and how could their attainment of knowledge improve. Most importantly this data highlights a deficiency in information regarding adverse oral effects. It is crucial that this topic be researched further and dental providers are educated on this subject matter to ensure the highest quality of care to dental patients.en_US
dc.language.isoen_USen_US
dc.subjectlow-dose methotrexateen_US
dc.subjectdiltiazemen_US
dc.subjectcyclosporineen_US
dc.subjectisotretinoinen_US
dc.subjectlisinoprilen_US
dc.subjectmucositisen_US
dc.subjectxerostomiaen_US
dc.subjectangular chelitisen_US
dc.subjectgingival hypertrophyen_US
dc.subject.lcshDentistry--Practice--New Mexico.
dc.subject.lcshPhysician practice patterns--New Mexico.
dc.subject.lcshDental care--New Mexico--Evaluation.
dc.subject.lcshDental surveys--New Mexico.
dc.subject.lcshDrug monitoring--New Mexico.
dc.subject.lcshDrugs--Side effects.
dc.subject.lcshMouth--Effect of drugs on.
dc.subject.lcshTeeth--Effect of drugs on.
dc.subject.lcshDrug interactions.
dc.titleA comparison of dental practitioners' knowledge of the adverse oral effects of pharmaceuticals; specifically, low-dose methotrexate, diltiazem, cyclosporine, istretinoin, and lisinoprilen_US
dc.typeThesisen_US
dc.description.degreeMaster of Science, Dental Hygieneen_US
dc.description.levelMastersen_US
dc.description.departmentDental Hygieneen_US
dc.description.advisorNathe, Christine
dc.description.committee-memberSanchez-Dils, Elaine
dc.description.committee-memberPlese, Melissa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record